These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

706 related articles for article (PubMed ID: 34015363)

  • 1. The COVID-19 vaccine development: A pandemic paradigm.
    Carneiro DC; Sousa JD; Monteiro-Cunha JP
    Virus Res; 2021 Aug; 301():198454. PubMed ID: 34015363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An overview of protein-based SARS-CoV-2 vaccines.
    Suryawanshi YR
    Vaccine; 2023 Oct; 41(42):6174-6193. PubMed ID: 37699784
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Application of Traditional Vaccine Development Strategies to SARS-CoV-2.
    Rando HM; Lordan R; Lee AJ; Naik A; Wellhausen N; Sell E; Kolla L; ; Gitter A; Greene CS
    mSystems; 2023 Apr; 8(2):e0092722. PubMed ID: 36861991
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New vaccine production platforms used in developing SARS-CoV-2 vaccine candidates.
    Ura T; Yamashita A; Mizuki N; Okuda K; Shimada M
    Vaccine; 2021 Jan; 39(2):197-201. PubMed ID: 33279318
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neutralizing-antibody-independent SARS-CoV-2 control correlated with intranasal-vaccine-induced CD8
    Ishii H; Nomura T; Yamamoto H; Nishizawa M; Thu Hau TT; Harada S; Seki S; Nakamura-Hoshi M; Okazaki M; Daigen S; Kawana-Tachikawa A; Nagata N; Iwata-Yoshikawa N; Shiwa N; Suzuki T; Park ES; Ken M; Onodera T; Takahashi Y; Kusano K; Shimazaki R; Suzaki Y; Ami Y; Matano T
    Cell Rep Med; 2022 Feb; 3(2):100520. PubMed ID: 35233545
    [TBL] [Abstract][Full Text] [Related]  

  • 7. COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants.
    Cevik M; Grubaugh ND; Iwasaki A; Openshaw P
    Cell; 2021 Sep; 184(20):5077-5081. PubMed ID: 34534444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current scenario of COVID-19 vaccinations and immune response along with antibody titer in vaccinated inhabitants of different countries.
    Hussain A; Rafeeq H; Asif HM; Shabbir S; Bilal M; Mulla SI; Franco M; Iqbal HMN
    Int Immunopharmacol; 2021 Oct; 99():108050. PubMed ID: 34426120
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Insights into COVID-19 Vaccine Development Based on Immunogenic Structural Proteins of SARS-CoV-2, Host Immune Responses, and Herd Immunity.
    Chaudhary JK; Yadav R; Chaudhary PK; Maurya A; Kant N; Rugaie OA; Haokip HR; Yadav D; Roshan R; Prasad R; Chatrath A; Singh D; Jain N; Dhamija P
    Cells; 2021 Oct; 10(11):. PubMed ID: 34831172
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SARS-CoV-2: vaccines in the pandemic era.
    Li DD; Li QH
    Mil Med Res; 2021 Jan; 8(1):1. PubMed ID: 33402220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A class II MHC-targeted vaccine elicits immunity against SARS-CoV-2 and its variants.
    Pishesha N; Harmand TJ; Rothlauf PW; Praest P; Alexander RK; van den Doel R; Liebeskind MJ; Vakaki MA; McCaul N; Wijne C; Verhaar E; Pinney W; Heston H; Bloyet LM; Pontelli MC; Ilagan MXG; Jan Lebbink R; Buchser WJ; Wiertz EJHJ; Whelan SPJ; Ploegh HL
    Proc Natl Acad Sci U S A; 2021 Nov; 118(44):. PubMed ID: 34654739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of SCB-2019 Coronavirus Disease 2019 Vaccine Compared With 4 Approved Vaccines.
    Ambrosino D; Han HH; Hu B; Liang J; Clemens R; Johnson M; Siber G; Goldblatt D
    J Infect Dis; 2022 Jan; 225(2):327-331. PubMed ID: 34888662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A review: Antibody-dependent enhancement in COVID-19: The not so friendly side of antibodies.
    Sánchez-Zuno GA; Matuz-Flores MG; González-Estevez G; Nicoletti F; Turrubiates-Hernández FJ; Mangano K; Muñoz-Valle JF
    Int J Immunopathol Pharmacol; 2021; 35():20587384211050199. PubMed ID: 34632844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunogenicity and safety of SARS-CoV-2 vaccines in clinical trials.
    Lim HX; Arip M; Yahaya AAA; Jazayeri SD; Poppema S; Poh CL
    Front Biosci (Landmark Ed); 2021 Nov; 26(11):1286-1304. PubMed ID: 34856768
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 Variants.
    Choi A; Koch M; Wu K; Dixon G; Oestreicher J; Legault H; Stewart-Jones GBE; Colpitts T; Pajon R; Bennett H; Carfi A; Edwards DK
    J Virol; 2021 Nov; 95(23):e0131321. PubMed ID: 34549975
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccines against SARS-CoV-2 variants and future pandemics.
    Park T; Hwang H; Moon S; Kang SG; Song S; Kim YH; Kim H; Ko EJ; Yoon SD; Kang SM; Hwang HS
    Expert Rev Vaccines; 2022 Oct; 21(10):1363-1376. PubMed ID: 35924678
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SARS-CoV-2 vaccine research and immunization strategies for improved control of the COVID-19 pandemic.
    Shao Y; Wu Y; Feng Y; Xu W; Xiong F; Zhang X
    Front Med; 2022 Apr; 16(2):185-195. PubMed ID: 35226300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A perspective on SARS-CoV-2 virus-like particles vaccines.
    Gao X; Xia Y; Liu X; Xu Y; Lu P; Dong Z; Liu J; Liang G
    Int Immunopharmacol; 2023 Feb; 115():109650. PubMed ID: 36649673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVID-19 vaccine and the cold chain implications for global adoption.
    Das MK
    Indian J Public Health; 2021; 65(3):307-310. PubMed ID: 34558497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frontrunners in the race to develop a SARS-CoV-2 vaccine.
    Russell RL; Pelka P; Mark BL
    Can J Microbiol; 2021 Mar; 67(3):189-212. PubMed ID: 33264067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.